Description: Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
Home Page: www.bioratherapeutics.com
BIOR Technical Analysis
4330 La Jolla Village Drive
San Diego,
CA
92122
United States
Phone:
855 293 2639
Officers
| Name | Title |
|---|---|
| Mr. Aditya P. Mohanty M.B.A. | CEO & Director |
| Mr. Eric d'Esparbes | Chief Financial Officer |
| Mr. Clarke Neumann J.D. | Gen. Counsel & Sec. |
| Eric Fox | VP of Fin. & Accounting & Treasurer |
| Mr. Troy Seelye | Chief Information Officer |
| Mr. George Gianakopoulos | Sr. VP of Sales |
| Ms. Robyn Hatton | Head of HR |
| Mr. Kevin Howe Ph.D. | Sr. VP of Strategic Operations |
| Dr. Sharat Singh Ph.D. | Head of Research |
| Dr. Paul Shabram M.B.A. | Head of Technical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 53.7639 |
| IPO Date: | 2020-06-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 124 |